This is a followup trial result to the first trial that reported 2.5 years of epigenetic age reversal This has interesting reports from the actual patients about how they feel and the changes it made to them. After the first trial I sent an email to see if I could do this but I have IBS which Fahy said would disqualify me.
Dr. Greg Fahy gives an update on the TRIIM-X clinical trial at EARD 2022.
The TRIIM-X clinical trial aims to understand how to create a personalized thymus regeneration regimen. By regenerating the thymus, the researchers hope to be able to prevent or reverse certain aspects of immune system aging.
FOLLOW US
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
https://www.lifespan.io.
https://www.facebook.com/lifespanio.
https://www.instagram.com/lifespan.io/
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀